INmune Bio, Inc. (INMB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 |
| Operating profit | $m | -31 | - | ||||||
| Net profit | $m | -12 | -30 | -27 | -30 | -42 | -46 | - | -19 |
| EPS reported | $ | -1.86 | - | ||||||
| Operating cashflow per share | $ | -0.85 | - | ||||||
| Capex per share | $ | 0.04 | - | ||||||
| FCF per share | $ | -0.89 | - | ||||||
| Free cash flow | $m | -24 | - | ||||||
| Net debt | $m | -25 | - | ||||||
| Book value equity | $m | 24 | - | ||||||
| Book value per share | $ | 0.88 | - | ||||||
| Number of shares | m | 26.59 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.76 | - | ||||||
| P/S LTM | x | 829.46 | - | ||||||
| P/FCF LTM | x | -1.76 | - | ||||||
| EV/EBITDA LTM | x | -0.39 | - | ||||||
| EV/Sales LTM | x | 355.12 | - | ||||||
| Earnings Yield LTM | % | -1.11% | - | ||||||
| FCF Yield | % | -56.96% | - | ||||||
| Quality | |||||||||
| ROE | % | -195.26% | - | ||||||
| ROIC | % | -1.26% | - | ||||||
| Operating margin | % | -617.38% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | -47248.0% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +257.14% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -22.85 | - | ||||||
| Net Debt/EBITDA | x | 0.52 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -1.05 | - | ||||||
| Gross debt/equity | x | 0.04 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free